1
|
Lucas AR, Crowson CS, O’Fallon WM and
Melton LJ III: The ups and downs of anorexia nervosa. Int J Eat
Disord. 26:397–405. 1999. View Article : Google Scholar : PubMed/NCBI
|
2
|
Tomita K, Haga H, Ishii G, et al: Clinical
manifestations of liver injury in patients with anorexia nervosa.
Hepatol Res. July 11–2013.(Epub ahead of print).
|
3
|
Kuboki T, Nomura S, Ide M, Suematsu H and
Araki S: Epidemiological data on anorexia nervosa in Japan.
Psychiatry Res. 62:11–16. 1996. View Article : Google Scholar
|
4
|
Sakada M, Tanaka A, Ohta D, et al: Severe
steatosis resulted from anorexia nervosa leading to fatal hepatic
failure. J Gastroenterol. 41:714–715. 2006. View Article : Google Scholar : PubMed/NCBI
|
5
|
Ludwig J, Viggiano TR, McGill DB and Oh
BJ: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a
hitherto unnamed disease. Mayo Clin Proc. 55:434–438.
1980.PubMed/NCBI
|
6
|
Sanyal AJ; American Gastroenterological
Association. AGA technical review on nonalcoholic fatty liver
disease. Gastroenterology. 123:1705–1725. 2002. View Article : Google Scholar : PubMed/NCBI
|
7
|
Rautou PE, Cazals-Hatem D, Moreau R, et
al: Acute liver cell damage in patients with anorexia nervosa: a
possible role of starvation-induced hepatocyte autophagy.
Gastroenterology. 135:840–848. 2008. View Article : Google Scholar : PubMed/NCBI
|
8
|
Narayanan V, Gaudiani JL, Harris RH and
Mehler PS: Liver function test abnormalities in anorexia nervosa -
cause or effect. Int J Eat Disord. 43:378–381. 2010.PubMed/NCBI
|
9
|
Dowman J, Arulraj R and Chesner I:
Recurrent acute hepatic dysfunction in severe anorexia nervosa. Int
J Eat Disord. 43:770–772. 2010. View Article : Google Scholar : PubMed/NCBI
|
10
|
Promrat K, Kleiner DE, Niemeier HM, et al:
Randomized controlled trial testing the effects of weight loss on
nonalcoholic steatohepatitis. Hepatology. 51:121–129. 2010.
View Article : Google Scholar : PubMed/NCBI
|
11
|
Belfort R, Harrison SA, Brown K, et al: A
placebo-controlled trial of pioglitazone in subjects with
nonalcoholic steatohepatitis. N Engl J Med. 355:2297–2307. 2006.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Matteoni CA, Younossi ZM, Gramlich T,
Boparai N, Liu YC and McCullough AJ: Nonalcoholic fatty liver
disease: a spectrum of clinical and pathological severity.
Gastroenterology. 116:1413–1419. 1999. View Article : Google Scholar : PubMed/NCBI
|
13
|
Seidell JC: Obesity, insulin resistance
and diabetes - a worldwide epidemic. Br J Nutr. 83(Suppl 1): S5–S8.
2000. View Article : Google Scholar : PubMed/NCBI
|
14
|
Smink FR, van Hoeken D and Hoek HW:
Epidemiology of eating disorders: incidence, prevalence and
mortality rates. Curr Psychiatry Rep. 14:406–414. 2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Osifo BO and Bolodeoku JO: Serum aspartate
and alanine aminotransferase activities in protein energy
malnutrition. Enzyme. 28:300–304. 1982.PubMed/NCBI
|
16
|
Meinhardt NG, Souto KE, Ulbrich-Kulczynski
JM and Stein AT: Hepatic outcomes after jejunoileal bypass: is
there a publication bias? Obes Surg. 16:1171–1178. 2006. View Article : Google Scholar : PubMed/NCBI
|
17
|
Suzaki A, Miura H, Takazoe M, Hamada T and
Kitamura S: Nonalcoholic steatohepatitis due to Crohn disease: a
lethal case report. Nihon Shokakibyo Gakkai Zasshi. 100:1212–1218.
2003.(In Japanese).
|
18
|
Furuta S, Ozawa Y, Maejima K, et al:
Anorexia nervosa with severe liver dysfunction and subsequent
critical complications. Intern Med. 38:575–579. 1999. View Article : Google Scholar : PubMed/NCBI
|
19
|
Aithal GP, Thomas JA, Kaye PV, et al:
Randomized, placebo-controlled trial of pioglitazone in nondiabetic
subjects with nonalcoholic steatohepatitis. Gastroenterology.
135:1176–1184. 2008. View Article : Google Scholar : PubMed/NCBI
|
20
|
Tomita K, Azuma T, Kitamura N, et al:
Pioglitazone prevents alcohol-induced fatty liver in rats through
up-regulation of c-Met. Gastroenterology. 126:873–885. 2004.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Hallakou S, Doaré L, Foufelle F, et al:
Pioglitazone induces in vivo adipocyte differentiation in the obese
Zucker fa/fa rat. Diabetes. 46:1393–1399. 1997. View Article : Google Scholar : PubMed/NCBI
|
22
|
Kletzien RF, Clarke SD and Ulrich RG:
Enhancement of adipocyte differentiation by an insulin-sensitizing
agent. Mol Pharmacol. 41:393–398. 1992.PubMed/NCBI
|
23
|
Laplante M, Festuccia WT, Soucy G, et al:
Mechanisms of the depot specificity of peroxisome
proliferator-activated receptor gamma action on adipose tissue
metabolism. Diabetes. 55:2771–2778. 2006. View Article : Google Scholar
|
24
|
Watkins PB: Idiosyncratic liver injury:
challenges and approaches. Toxicol Pathol. 33:1–5. 2005. View Article : Google Scholar : PubMed/NCBI
|
25
|
Wang H, Khaoustov VI, Krishnan B, et al:
Total parenteral nutrition induces liver steatosis and apoptosis in
neonatal piglets. J Nutr. 136:2547–2552. 2006.PubMed/NCBI
|
26
|
Matsumoto T, Yamasaki S, Arakawa A, et al:
Exposure to a high total dosage of glucocorticoids produces
non-alcoholic steatohepatits. Pathol Int. 57:388–389. 2007.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Leuschner UF, Lindenthal B, Herrmann G, et
al: High-dose ursodeoxycholic acid therapy for nonalcoholic
steatohepatitis: a double-blind, randomized, placebo-controlled
trial. Hepatology. 52:472–479. 2010. View Article : Google Scholar : PubMed/NCBI
|
28
|
Tobari M, Hashimoto E, Yatsuji S, Torii N
and Shiratori K: Imaging of nonalcoholic steatohepatitis:
advantages and pitfalls of ultrasonography and computed tomography.
Intern Med. 48:739–746. 2009. View Article : Google Scholar : PubMed/NCBI
|